Pharma stocks battered, many touch new lows

Shares of pharmaceutical companies got hammered down in the Monday stock market meltdown amid the tariff war set in motion last week by the U.S. with its reciprocal tariffs.

All 20 companies forming part of the Nifty Pharma were in the red even as the sectoral index of the National Stock Exchange ended 2.75% lower at 19,995.50 points. Of them, shares of as many as six companies touched their 52-week low.

While Aurobindo Pharma, Dr. Reddy’s Laboratories and Zydus Lifesciences shares opened at their 52-week low, Gland Pharma, Natco Pharma and JB Chemicals and Pharmaceuticals shares touched a new low intra-day on the NSE. Cipla shares on BSE touched 52-week low.

The decline in the shares prices of the 20 companies part of Nifty Pharma index ranged from less than 1% to as much as 6% with Biocon ending 5.99% lower at ₹308.15 each.

Though pharma did not figure in the list of goods that face the reciprocal tariff, the fear of being slapped with the levy remains for the drug makers. Hours after unleashing reciprocal tariffs, U.S. President Donald Trump had told media the tariff for pharma and semiconductors is also on the cards. It will “happen in near future… under review right now. Looking at pharma as a separate category and will be announcing that in not too distant future,” he had said, adding the tariff will be at a level never seen before.

  • Related Posts

    WHO launches new primary health care course to strengthen health systems globally

    Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    WHO launches new primary health care course to strengthen health systems globally

    WHO launches new primary health care course to strengthen health systems globally

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert